Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

Mills & Reeve 100 Hills Rd, CB2 1PH, Cambridge

OBN C-Suite Breakfast: ‘The Art of Dealmaking’

OBN's round table C-Suite Discussions are designed exclusively for senior leaders (C-Suite or equivalent) from life sciences organisations, whether R&D or those involved in providing [...]

OBN Science Social

Attendees will have the opportunity to engage with the Cancer Research Horizons Ventures team, a dedicated group of experts specialising in identifying and nurturing high-potential, [...]

BioTrinity 2025

BioTrinity 2025 will be OBN's flagship two-day conference, taking place in its 19th year. The event will feature presentations from R&D companies at Series A [...]

Go to Top